← SynDRA
DACOMITINIB ANHYDROUS
SynDRA canonical compound SYN0033402 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | EGFR | ERBB2 | ERBB4 |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
All known targets
- EGFR
- ERBB2
- ERBB4
- GAK
- JAK3
- LCK
- RIPK2
- RIPK3
- SRC
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- ERBB2 INHIBITOR
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- ERBB4 INHIBITOR
- Receptor protein-tyrosine kinase erbB-4 inhibitor
- ERBB4 ANTAGONIST
- ERBB2 ANTAGONIST
- EGFR ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SYK
- DRD2
- KCNH2
- AAK1
- PAICS
- OLA1
- NUAK2
- NTRK1
- NR1I2
- NQO2
- NLK
- NEK9
- NEK7
- NEK6
- NEK3
- NEK2
- NEK1
- NDUFA13
- NAT10
- OPA1
- PDE3A
- PAK4
- MYLK
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- PIM2
- PIM1
- PHKG2
- PGR
- PFKP
- PEBP1
- PDXK
- PDK1
- PDGFRB
- PDE4D
- MYLK3
- MYH14
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- KSYK
- PNMT
- PARP1
- NTMT1
- NTM1A
- NSD2
- NNMT
- IL3
- CP2D6
- IFNG
- IFNB1
- HNMT
- HLAB
- GNMT
- GAMT
- TP53
Drug classes
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- VIZIMPRO
- Vizimpro
- dacomitinib
- dacomitinib hydrate
- vizimpro
- PF-00299804-03
- PF-00299804
- PF-299
- PF-299804
- PF-804
- Pf-00299804
- Dacomitinib
- PF299804
- Dacomitinib (PF299804, PF299)
- Dacomitinib (PF299804)
- 2XJX250C20
- PF 00299804-03
- Dacomitinib (INN)
- DACOMITINIB [INN]
- PF-299804 (Dacomitinib PF-00299804)
- Dacomitinib [USAN:INN]
- dacomitinibum
- UNII-2XJX250C20
- PF299
- DACOMITINIB [WHO-DD]
- MLS006011275
- GTPL7422
- CHEMBL2110732
- CHEBI:91466
- DTXSID50149493
- EX-A030
- CHEBI:132268
- BDBM112499
- Dacomitinib (PF-00299804)
- AMY21292
- BCP02530
- MFCD19443734
- NSC765888
- NSC800084
Reported adverse events
- Alopecia
- Asthenia
- Conjunctivitis
- Dermatitis
- Dry skin
- Mouth ulceration
- Nausea
- Paronychia
- Pruritus
- Rash
- Stomatitis
- Decreased appetite
Look up DACOMITINIB ANHYDROUS in the interactive SynDRA portal →